**INTERNEURON** Sex ohne Kondom?** - 500 Beiträge pro Seite
eröffnet am 10.03.01 15:15:38 von
neuester Beitrag 10.03.01 15:56:32 von
neuester Beitrag 10.03.01 15:56:32 von
Beiträge: 9
ID: 356.884
ID: 356.884
Aufrufe heute: 0
Gesamt: 282
Gesamt: 282
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 33 Minuten | 6247 | |
vor 38 Minuten | 5007 | |
vor 41 Minuten | 4148 | |
vor 47 Minuten | 3758 | |
vor 33 Minuten | 2585 | |
heute 14:53 | 1943 | |
heute 15:18 | 1918 | |
heute 13:07 | 1476 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.181,34 | +1,40 | 235 | |||
2. | 2. | 1,1100 | -19,57 | 118 | |||
3. | 3. | 0,1905 | +0,79 | 97 | |||
4. | 5. | 9,3500 | +1,14 | 63 | |||
5. | 4. | 171,73 | +0,91 | 54 | |||
6. | Neu! | 0,4250 | -1,16 | 39 | |||
7. | Neu! | 11,905 | +14,97 | 36 | |||
8. | Neu! | 4,7790 | +6,56 | 35 |
Bald wieder Sex ohne Kondom?
Könnte die Krankheit AIDS bald der Vergangenheit angehören? Ein
Unternehmen namens
Interneur. Pharmaceuticals Inc. (WKN 883147)
hat ein Mittel erfunden, daß das Risiko der Ansteckungsgefahr von HIV auf 0
reduzieren könnte! Das Mittel ist ein Gel, welches im Genitalbereich aufgetragen
wird und somit potentielle Ansteckungsviren nicht übertragen soll!
Das sind Zukunftsaussichten, die enorme Phantasien aufkommen lässt.
Das Mittel wird derzeit in Afrika getestet (an Menschen!)
Wer mehr über das Unternehmen erfahren will: www.interneuron.com
Der Wert hat sich übrigens seit Januar diesen Jahres verdreifacht!!!!!
Check it out!
Könnte die Krankheit AIDS bald der Vergangenheit angehören? Ein
Unternehmen namens
Interneur. Pharmaceuticals Inc. (WKN 883147)
hat ein Mittel erfunden, daß das Risiko der Ansteckungsgefahr von HIV auf 0
reduzieren könnte! Das Mittel ist ein Gel, welches im Genitalbereich aufgetragen
wird und somit potentielle Ansteckungsviren nicht übertragen soll!
Das sind Zukunftsaussichten, die enorme Phantasien aufkommen lässt.
Das Mittel wird derzeit in Afrika getestet (an Menschen!)
Wer mehr über das Unternehmen erfahren will: www.interneuron.com
Der Wert hat sich übrigens seit Januar diesen Jahres verdreifacht!!!!!
Check it out!
@ wallgrekk
wenn das stimmt,wird sich auch die Bevölkerung in Afrika verdreifachen........und wenn die dann alle NM-Aktien kaufen,dürfte ich in ca. 20 Jahren reich sein!!
M.
wenn das stimmt,wird sich auch die Bevölkerung in Afrika verdreifachen........und wenn die dann alle NM-Aktien kaufen,dürfte ich in ca. 20 Jahren reich sein!!
M.
Mann, bist Du geschmacklos!
Du findest sowas auch noch lustig...
echt bemitleidenswert.
Du findest sowas auch noch lustig...
echt bemitleidenswert.
Oh Mann,
jetzt habe ich aber ganz schön in´s Fettnäpfchen getreten.......
War nicht ernst gemeint......!!
M.
jetzt habe ich aber ganz schön in´s Fettnäpfchen getreten.......
War nicht ernst gemeint......!!
M.
@moneyfutsch:
Okay. Bin nicht nachtragend. Erst denken, dann schreiben.
Cheers!
Okay. Bin nicht nachtragend. Erst denken, dann schreiben.
Cheers!
Interneuron`s PRO 2000 Shown to Protect Against Viral Infection in Primate Model of Sexual HIV Transmission
Results To Be Presented At Chicago AIDS Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 6, 2001--Researchers have demonstrated that a vaginal microbicide under
development by Interneuron Pharmaceuticals, Inc. (NASDAQ: IPIC - news) can afford protection against viral infection in a rhesus
monkey model of the sexual transmission of HIV (human immunodeficiency virus), the virus that causes AIDS (acquired
immunodeficiency syndrome).
In a study supported by the National Institutes of Health (NIH) and conducted by the Southern Research Institute (SRI), most
animals treated with the microbicide, known as PRO 2000, remained uninfected and healthy following exposure to a highly
infectious dose of an HIV-like virus when compared to untreated animals. Complete findings from the study will be presented by Dr.
Mark Lewis of SRI at the 8th Conference on Retroviruses and Opportunistic Infections in Chicago (February 4 - 8, 2001).
``These findings strengthen the rationale for developing PRO 2000 as a topical microbicide to prevent HIV infection,`` said Dr. Albert
Profy, vice president of preclinical development at Interneuron. ``We believe this protection is conferred through prevention of HIV
entry into susceptible human cells. The additional scientific evidence from the study provides further justification for expanded
human testing.``
PRO 2000 is an antimicrobial compound formulated into a gel that is vaginally applied prior to sexual intercourse. The compound is
designed to prevent the sexual transmission of HIV and other disease-causing microbes, including herpes simplex viruses,
Chlamydia trachomatis and Neisseria gonorrhoeae.
In the SRI study, female rhesus macaque monkeys were pre-treated with a hormonal contraceptive to increase their susceptibility to
infection. A month later, each animal in the treatment group received a single, intra-vaginal dose of PRO 2000 (at one of three
strengths) and all animals were then challenged intra-vaginally with a hybrid simian-human immunodeficiency virus (SHIV), a simian
virus that has the envelope of HIV. Because PRO 2000 appears to attack the HIV envelope, the use of SHIV rather than an
unmodified simian virus may be more relevant to the human situation.
Two weeks after exposure, seven of seven untreated control monkeys showed evidence of infection, and all developed early signs of
AIDS during the course of the study. By contrast, six of seven animals treated with 4% PRO 2000 remained uninfected and healthy
over the 16-week course of the study. Five of seven animals treated with 2% PRO 2000 and two of seven treated with 0.5% PRO
2000 also remained uninfected and healthy. Of the five animals in the 0.5% group that appeared to be infected, all were able to
control the virus, and none progressed to developing AIDS. The differences in levels of circulating virus between each of the PRO
2000 treated groups and the control group were all statistically significant (p less than 0.04).
The new findings confirm and extend the results of an earlier macaque study in which 4% PRO 2000 showed evidence for protection
in a small number of animals. Though the precise relevance of the monkey model to the human situation has yet to be determined,
the viral levels used to infect these animals are believed to be significantly higher than the dose to which women are typically
exposed during a single sexual encounter. In previous animal studies, PRO 2000 was shown to prevent herpes infection in mice and
to reduce pregnancy rates in rabbits.
PRO 2000 at the strengths found effective in the monkey study was previously judged to be safe and well tolerated in human Phase
1 clinical trials involving healthy, sexually abstinent women. Preliminary results from a NIH-supported Phase 1/Phase 2 clinical trial
suggest the product has a promising safety profile in healthy, sexually active women as well. Interneuron believes that these data
provide a strong rationale for accelerated Phase 2 and Phase 3 clinical testing to assess the long-term safety and protective
efficacy of PRO 2000 in women at risk for HIV infection. A Phase 2 clinical trial of the product is scheduled to begin in Africa later
this year, with support from the European Commission.
Results To Be Presented At Chicago AIDS Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 6, 2001--Researchers have demonstrated that a vaginal microbicide under
development by Interneuron Pharmaceuticals, Inc. (NASDAQ: IPIC - news) can afford protection against viral infection in a rhesus
monkey model of the sexual transmission of HIV (human immunodeficiency virus), the virus that causes AIDS (acquired
immunodeficiency syndrome).
In a study supported by the National Institutes of Health (NIH) and conducted by the Southern Research Institute (SRI), most
animals treated with the microbicide, known as PRO 2000, remained uninfected and healthy following exposure to a highly
infectious dose of an HIV-like virus when compared to untreated animals. Complete findings from the study will be presented by Dr.
Mark Lewis of SRI at the 8th Conference on Retroviruses and Opportunistic Infections in Chicago (February 4 - 8, 2001).
``These findings strengthen the rationale for developing PRO 2000 as a topical microbicide to prevent HIV infection,`` said Dr. Albert
Profy, vice president of preclinical development at Interneuron. ``We believe this protection is conferred through prevention of HIV
entry into susceptible human cells. The additional scientific evidence from the study provides further justification for expanded
human testing.``
PRO 2000 is an antimicrobial compound formulated into a gel that is vaginally applied prior to sexual intercourse. The compound is
designed to prevent the sexual transmission of HIV and other disease-causing microbes, including herpes simplex viruses,
Chlamydia trachomatis and Neisseria gonorrhoeae.
In the SRI study, female rhesus macaque monkeys were pre-treated with a hormonal contraceptive to increase their susceptibility to
infection. A month later, each animal in the treatment group received a single, intra-vaginal dose of PRO 2000 (at one of three
strengths) and all animals were then challenged intra-vaginally with a hybrid simian-human immunodeficiency virus (SHIV), a simian
virus that has the envelope of HIV. Because PRO 2000 appears to attack the HIV envelope, the use of SHIV rather than an
unmodified simian virus may be more relevant to the human situation.
Two weeks after exposure, seven of seven untreated control monkeys showed evidence of infection, and all developed early signs of
AIDS during the course of the study. By contrast, six of seven animals treated with 4% PRO 2000 remained uninfected and healthy
over the 16-week course of the study. Five of seven animals treated with 2% PRO 2000 and two of seven treated with 0.5% PRO
2000 also remained uninfected and healthy. Of the five animals in the 0.5% group that appeared to be infected, all were able to
control the virus, and none progressed to developing AIDS. The differences in levels of circulating virus between each of the PRO
2000 treated groups and the control group were all statistically significant (p less than 0.04).
The new findings confirm and extend the results of an earlier macaque study in which 4% PRO 2000 showed evidence for protection
in a small number of animals. Though the precise relevance of the monkey model to the human situation has yet to be determined,
the viral levels used to infect these animals are believed to be significantly higher than the dose to which women are typically
exposed during a single sexual encounter. In previous animal studies, PRO 2000 was shown to prevent herpes infection in mice and
to reduce pregnancy rates in rabbits.
PRO 2000 at the strengths found effective in the monkey study was previously judged to be safe and well tolerated in human Phase
1 clinical trials involving healthy, sexually abstinent women. Preliminary results from a NIH-supported Phase 1/Phase 2 clinical trial
suggest the product has a promising safety profile in healthy, sexually active women as well. Interneuron believes that these data
provide a strong rationale for accelerated Phase 2 and Phase 3 clinical testing to assess the long-term safety and protective
efficacy of PRO 2000 in women at risk for HIV infection. A Phase 2 clinical trial of the product is scheduled to begin in Africa later
this year, with support from the European Commission.
Interneuron war vor Jahren mal ein echter Biotechliebling
der Amis da standen die mal bei 50 DM 1997 hat damals sogar
Börse Online Empfohlen das Problem ist nur das die damals
ein mittel gegen Fettleibigkeit auf dem Markt gebracht
haben REDUX,nur da sind dann ein paar leute Abgenippelt,
das ist der Grund warum die seit 2Jahren zwischen 2-5$
rumdümpeln,das Verfahren vor US-Gerichten ist auch noch nicht
beendet,da geht es um enorm hohe Entschädigungszahlungen
und das wird auch noch dauern.
der Amis da standen die mal bei 50 DM 1997 hat damals sogar
Börse Online Empfohlen das Problem ist nur das die damals
ein mittel gegen Fettleibigkeit auf dem Markt gebracht
haben REDUX,nur da sind dann ein paar leute Abgenippelt,
das ist der Grund warum die seit 2Jahren zwischen 2-5$
rumdümpeln,das Verfahren vor US-Gerichten ist auch noch nicht
beendet,da geht es um enorm hohe Entschädigungszahlungen
und das wird auch noch dauern.
Die alles entscheidende Frage ist doch wie das Zeug schmeckt.
Du sollst das Zeug doch nicht essen, Mensch.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
224 | ||
124 | ||
105 | ||
64 | ||
55 | ||
39 | ||
38 | ||
35 | ||
27 | ||
26 |
Wertpapier | Beiträge | |
---|---|---|
21 | ||
21 | ||
20 | ||
18 | ||
18 | ||
17 | ||
17 | ||
17 | ||
16 | ||
16 |